New
Research Assistant I- iPSC & Neuromuscular Disease Research
Boston Children's Hospital | |
$44657.60-$69773.60 Annual
| |
dental insurance, 403(b)
| |
United States, Massachusetts, Boston | |
Oct 28, 2026 | |
|
Position Summary/ Department Summary:
We offer an opportunity to support cutting-edge neuromuscular disease research in the laboratory of Dr. Elizabeth Engle at Boston Children's Hospital and Harvard Medical School (http://kirbyneuro.org/EngleLab/). Our work uses human induced pluripotent stem cells (iPSCs), spinal cord organoids, skeletal muscle, and functional neuromuscular junction (NMJ) models to study spinal muscular atrophy (SMA) and therapeutic strategies that restore motor neuron-muscle connectivity. This position is ideal for a self-motivated and detail-oriented individual interested in developing a broad skill set in stem cell culture, organoid differentiation, microscopy, functional imaging, molecular biology, single-cell profiling, and drug screening. The successful candidate will join the Eagles Lab as a Laboratory Research Assistant I, working under the supervision of Dr. Kuchuan Chen. Evenings and weekend hours will occasionally be required for cell culture experiments. This position is looking for someone to start ASAP. Key Responsibilities:
Minimum Qualifications Education:
The posted pay range is Boston Children's reasonable and good-faith expectation for this pay at the time of posting. Any base pay offer provided depends on skills, experience, education, certifications, and a variety of other job-related factors. Base pay is one part of a comprehensive benefits package that includes flexible schedules, affordable health, vision and dental insurance, child care and student loan subsidies, generous levels of time off, 403(b) Retirement Savings plan, Pension, Tuition and certain License and Certification Reimbursement, employee discounts and discounted commuter benefits at certain locations. Experience the benefits of passion and teamwork. | |
$44657.60-$69773.60 Annual
dental insurance, 403(b)
Oct 28, 2026